Review article:: systemic and topical steroids in inflammatory bowel disease

被引:19
作者
Schölmerich, J [1 ]
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany
关键词
D O I
10.1111/j.1365-2036.2004.02059.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steroids are still widely used in the treatment of inflammatory bowel diseases. Pharmacological studies have shown that there is no major abnormality in the pharmacokinetics of steroids in these disorders. Foam preparations with rectal application decrease the bioavailability to low levels, eliminating systemic complications. For oral use, 'nonsystemic' steroids have been developed. In ulcerative colitis. steroids are rarely needed as 5-aminosalicylates are effective in the majority of patients. This is true for rectal application in distal colitis, as well as in more extensive disease. In Crohn's disease, steroids are more often used; however, in population-based studies, less than 50% of patients have been treated with steroids, as there are alternative treatments available for the large group of patients with mild to moderate activity. For those patients needing steroid treatment, budesonide seems to be a good choice in active disease, but has not shown convincing effects in the maintenance of remission over longer periods of time. There is no place for long-term steroid treatment in ulcerative colitis and very little in Crohn's disease - immunosuppression with azathioprine or related drugs is certainly the better alternative.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 50 条
  • [41] Review article: inflammatory bowel disease - empowering the patient and improving outcome
    Robinson, A
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 84 - 87
  • [42] Review article: patients' fears and unmet needs in inflammatory bowel disease
    Irvine, EJ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 54 - 59
  • [43] Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease
    Chapman, Thomas P.
    Gomes, Catarina Frias
    Louis, Edouard
    Colombel, Jean-Frederic
    Satsangi, Jack
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 73 - 84
  • [44] Review article: anti-adhesion therapies for inflammatory bowel disease
    Lobaton, T.
    Vermeire, S.
    Van Assche, G.
    Rutgeerts, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (06) : 579 - 594
  • [45] Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
    Munkholm, P
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 : 1 - 5
  • [46] Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease
    Gassull, M. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 : 90 - 95
  • [47] Review article: anti-tryptase therapy in inflammatory bowel disease
    Yoshida, N.
    Isozaki, Y.
    Takagi, T.
    Takenaka, S.
    Uchikawa, R.
    Arizono, N.
    Yoshikawa, T.
    Okanoue, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 : 249 - 255
  • [48] Review article: explaining risks of inflammatory bowel disease therapy to patients
    Siegel, C. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (01) : 23 - 32
  • [49] Review article: the aetiopathogenesis of inflammatory bowel disease - immunology and repair mechanisms
    Dignass, AU
    Baumgart, DC
    Sturm, A
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 9 - 17
  • [50] Review article: the psychosexual impact of inflammatory bowel disease in male patients
    O'Toole, A.
    Winter, D.
    Friedman, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1085 - 1094